MedTrace Logo

Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma

NCT00041236 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2012-07-18

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have advanced soft tissue sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

exatecan mesylate

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Peter Reichardt, MD · Robert Roessle Klinik

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2004-12-31

Countries

  • Belgium
  • Denmark
  • Germany
  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00041236 on ClinicalTrials.gov